Prostate Cancer KOL Snapshot Report

Original price was: $7,500.00.Current price is: $497.00.

The Prostate Cancer KOL Market Snapshot will address these important questions with advanced prostate cancer key opinion leaders from the US, EU and Asia Pacific to guide clinical and commercial decisions in both castrate-sensitive and castrate-resistant prostate cancer settings.

SKU: CMR-01 Category:


Cost-Efficient Access to Key KOL Insights. Avoid expensive and time-consuming research.


¬†“Highly recommend this report for those interested in understanding current and future developments in Prostate Cancer. The report’s depth and coverage are impressive and the Cheat Code is helpful in quickly gaining the key insights.”¬†

РMarketing Executive, Pharmaceutical Company 


  • Key decision drivers
  • Treatment preferences
  • Regulatory agency perspectives
  • Catalysts for future prescribing behavior
  • And much more

Our respondents are KOLs with an average of 125 co-authored clinical trial publications, committee participation, and 34 years of experience!

Perfect for marketers, executives, administrators, and investors, this concise report, crafted by top global KOLs, provides comprehensive insights on:

  • Treatment preferences across prostate cancer stages
  • Key decision drivers at the mechanism and product levels
  • Factors influencing satisfaction or dissatisfaction with current treatments
  • Market volatility and potential disruptions in the next 12 months and 2-5 years
  • Drugs positioned to change standards of care
  • Catalysts for future prescribing changes

Covering current prescribing behavior and future directions, the report delves into:

  • Sequencing of treatment options in metastatic castration-resistant prostate cancer (mCRPC)
  • Impact of PARP inhibitors in 1st line mCRPC patients
  • Evolution of docetaxel’s role in metastatic castration-sensitive prostate cancer (mCSPC)
  • Assessment of best-in-class androgen receptor pathway inhibitors
  • Usage expectations of Pluvicto and other radioligand programs
  • Precision medicine’s role in treatment selection and biomarkers
  • Impact of PSMA PET on the prostate cancer treatment landscape
  • Regulatory agency perspectives on endpoints in localized, locally advanced, and metastatic prostate cancer